Research programme: diabetes therapy - Phylogica/Garvan Institute of Medical Research

Drug Profile

Research programme: diabetes therapy - Phylogica/Garvan Institute of Medical Research

Alternative Names: Diabetes therapy research programme - Phylogica

Latest Information Update: 19 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phylogica
  • Developer Garvan Institute of Medical Research; Phylogica
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 03 Mar 2006 Phylogica and Garvan Institute of Medical Research have entered into a collaboration agreement for the development of Phylomer® drugs for diabetes
  • 18 Aug 2005 The programme is available for licensing (http://www.phylogica.com)
  • 18 Aug 2005 Early research in Diabetes mellitus in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top